Document is current
Any future updates will be listed below
-
Authors
Deaton, Aimee M. https://orcid.org/0000-0003-0365-3077
Dubey, Aditi
Ward, Lucas D. https://orcid.org/0000-0002-8017-809X
Dornbos, Peter
Flannick, Jason https://orcid.org/0000-0002-3618-795X
,
Yee, Elaine
Ticau, Simina
Noetzli, Leila
Parker, Margaret M.
Hoffing, Rachel A.
Willis, Carissa
Plekan, Mollie E.
Holleman, Aaron M.
Hinkle, Gregory
Fitzgerald, Kevin
Vaishnaw, Akshay K.
Nioi, Paul
-
Funding
Funding for this research was provided by:
Alnylam Pharmaceuticals
U.S. Department of Health & Human Services | National Institutes of Health (R01DK125490)
- License Information
-
More Information
Article History
Received: 20 December 2021
Accepted: 1 July 2022
First Online: 27 July 2022
Competing interests
: A.Deaton, A.Dubey, L.D.W., E.Y., S.T., L.N., R.A.H., C.W., M.E.P., A.M.H., K.F., A.K.V. and P.N. are employees and stockholders of Alnylam Pharmaceuticals. G.H. is an employee and stockholder of Alnylam Pharmaceuticals and a paid consultant to 54Gene. M.M.P. is a former employee and stockholder of Alnylam Pharmaceuticals and a current employee and stockholder of Beam Therapeutics. As of April 2022, P.D. is an employee and stockholder of Regeneron Pharmaceuticals. J.F. has no competing interests.
